Carcinoma Breast Stage IV Clinical Trial
Official title:
Role of Surgery for the Primary in Patients With Breast Cancer Stage IV - A Prospective Randomized Multicenter Controlled Trial
Verified date | February 2015 |
Source | National Cancer Institute, Thailand |
Contact | n/a |
Is FDA regulated | No |
Health authority | Thailand: Ministry of Public Health |
Study type | Interventional |
The purpose of this study is to determine benefits of surgery for the primary in patients with breast cancer stage IV in randomized controlled study.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | August 2019 |
Est. primary completion date | August 2014 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Healthy breast cancer stage IV patients with resectable primary breast tumor. - Resectable breast cancer stage IV patients who well response of visceral metastasis to systemic therapy and fit for surgery. Exclusion Criteria: - Breast cancer stage IV patients with local complication of primary breast tumor that require surgery for palliation such as uncontrolled bleeding,large and non-healing ulcer or intractable pain. - Breast cancer stage IV patients with unresectable primary breast tumor or extensive chest wall disease. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Thailand | Division Head & Neck and Breast, Department of Surgery. Faculty of Medicine Siriraj Hospital | Bangkok Noi | Bangkok |
Thailand | Department of Surgery, Faculty of Medicine Vajira Hospital. | Dusit | Bangkok |
Thailand | Khon Kaen University | Muang | Khon Kaen |
Thailand | Chonburi Cancer Hospital | Muang Chonburi | Chonburi |
Thailand | Suratthani Cancer Hospital | Muang Suratthani | Suratthani |
Thailand | Udon Thani Cancer Hospital | Muang Udon Thani | Udon Thani |
Thailand | Phyathai 2 Hospital | PhyaThai | Bangkok |
Thailand | National Cancer Institute | Ratchathewi | Bangkok |
Thailand | Phramongkutklao Hospital | Ratchathewi | Bangkok |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute, Thailand | Vichaiyut Hospital |
Thailand,
Gnerlich J, Jeffe DB, Deshpande AD, Beers C, Zander C, Margenthaler JA. Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer: analysis of the 1988-2003 SEER data. Ann Surg Oncol. 2007 Aug;14(8):2187-94. Epub 2007 May 24. — View Citation
Khan SA, Stewart AK, Morrow M. Does aggressive local therapy improve survival in metastatic breast cancer? Surgery. 2002 Oct;132(4):620-6; discussion 626-7. — View Citation
Neuman HB, Morrogh M, Gonen M, Van Zee KJ, Morrow M, King TA. Stage IV breast cancer in the era of targeted therapy: does surgery of the primary tumor matter? Cancer. 2010 Mar 1;116(5):1226-33. doi: 10.1002/cncr.24873. — View Citation
Nguyen DA, Truong PT, Lesperance ML et al. Can locoregional treatment of the primary tumor improve outcomes for women with stage IV breast cancer at diagnosis? Proceedings of 53rd Annual Meeting of the American Society for Radiation Oncology. Int. J. Radiat. Oncol. Biol. Phys. (2011)
Rapiti E, Verkooijen HM, Vlastos G, Fioretta G, Neyroud-Caspar I, Sappino AP, Chappuis PO, Bouchardy C. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol. 2006 Jun 20;24(18):2743-9. Epub 2006 May 15. — View Citation
Shien T, Kinoshita T, Shimizu C, Hojo T, Taira N, Doihara H, Akashi-Tanaka S. Primary tumor resection improves the survival of younger patients with metastatic breast cancer. Oncol Rep. 2009 Mar;21(3):827-32. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall survival | Five years | No | |
Secondary | Quality of life & Uncontrolled chest wall disease | Five years | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03511781 -
Palliative Hypofractionated Radiotherapy in Advanced Incurable Breast Cancer
|
N/A | |
Completed |
NCT00199212 -
PS-341 in Combination With Herceptin in Advanced Breast Cancer That Overexpresses HER-2
|
Phase 1 | |
Recruiting |
NCT06281860 -
Treatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration
|
Phase 1 | |
Active, not recruiting |
NCT02755272 -
A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
|
Phase 2 | |
Withdrawn |
NCT02140437 -
Fulvestrant Combined Anastrozole Versus Anastrozole in Luminal A-like Postmenopausal ABC
|
Phase 2 | |
Terminated |
NCT02183805 -
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Metastatic Triple-negative Breast Cancer
|
Phase 2 | |
Terminated |
NCT01531764 -
BIBW 2992 (Afatinib) and Vinorelbine
|
Phase 2 | |
Completed |
NCT00669565 -
Safety and Efficacy Study of Bavituximab Plus Paclitaxel and Carboplatin to Treat Breast Cancer
|
Phase 2 | |
Completed |
NCT01631552 -
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT02161315 -
Steroid Aromatase Inhibitors Versus Progestogens for nSAID-resistanced Late Stage Breast Cancer
|
N/A | |
Completed |
NCT00433095 -
Vinorelbine (Oral) Plus Trastuzumab for 1st-line Treatment of HER2/Neu Overexpressing Breast Cancer
|
Phase 2 |